Company intelligence / Profile preview

Abkyu

Boston, Massachusetts, United Statesabkyu.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Abkyu specializes in rapid in vivo discovery of camelid single-domain antibodies (VHHs or nanobodies) using advanced genetic immunization, immune profiling, proprietary DNA protocols, deep NGS, and machine learning. The company offers custom library construction and delivers fully owned partner deliverables with no royalties or milestones. Their workflow enables early capture of high-affinity VHHs with ideal developability characteristics for diverse therapeutic modalities.

Therapeutic areas: Other
Modalities: Nanobody therapyAntibodyAntibody-drug conjugateCell therapyRadiopharmaceutical (for radiotherapies)
Industry: Drug Discovery Services

Partnerships

HubXchange partnership program participant

Beyond the preview

Go deeper on Abkyu.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abkyu.

Explore the full profile